tct20xxdes重要研究回顧李浪廣西心血管病研究所廣西醫(yī)-文庫吧
2025-09-08 14:56 本頁面
【正文】 11 Cardiac Death MI TVR Sirolimuseluting stent % Everolimuseluting stent % Hazard Ratio = , 95% CI – , p= Sirolimuseluting stent % Everolimuseluting stent % Hazard Ratio = , 95% CI – , p= Everolimuseluting stent % Sirolimuseluting stent % Hazard Ratio = , 95% CI – , p= MACE事件率無顯著差異 Hazard Ratio = , 95% CI – , p= Sirolimuseluting stent % Everolimuseluting stent % Definite Stent Thrombosis 12 TLR Sirolimuseluting stent % Everolimuseluting stent % Hazard Ratio = , 95% CI – , p= Sirolimuseluting stent % Everolimuseluting stent % Hazard Ratio = , 95% CI – , p= Definite or Probable tent Thrombosis 9個月 TLR 及可能的支架內(nèi)血栓均無差異 13 ９個月 時預(yù)先設(shè)定亞組人群 MACE事件率均無差異 Jensen et al. Presented at TCT 2020 in Washington, DC. Overall STEMI yes STEMI no Previous PCI yes Previous PCI no Previous MI yes Previous MI no One stent per patient yes One stent per patient no Multivessel disease yes Multivessel disease no Male yes Male no Lesion not type C Lesion type C LAD yes LAD no Diabetes mellitus yes Diabetes mellitus no Age 65 Age ≤65 Acute coronary syndrome yes Acute coronary syndrome no 35/773 () 36/1188 () ( ) 33/617 () 36/630 () ( ) 37/719 () 41/746 () ( ) 31/671 () 31/638 () ( ) 58/1196 () 56/1188 () ( ) 10/194 () 16/196 () ( ) 30/705 () 38/665 () ( ) 38/685 () 34/719 () ( ) 41/580 () 49/602 () ( ) 27/810 () 23/782 () ( ) 14/335 () 19/343 () ( ) 54/1055 () 53/1041 () ( ) 51/1166 () 60/1182 () ( ) 17/224 () 12/202 () ( ) 32/550 () 36/511 () ( ) 34/833 () 33/864 () ( ) 41/947 () 46/955 () ( ) 21/276 () 17/259 () ( ) 50/963 () 47/964 () ( ) 13/264 () 16/250 () ( ) 61/1268 () 64/1239 () ( ) 7/122 () 8/145 () ( ) 68/1390 () 72/1384 () ( ) Events (%) Xience174。 Stent CYPHER174。 Stent Hazard Ratio (95% CI) P Value for Interaction Xience174。 better CYPHER174。 better 14 結(jié) 論 ? 兩組支架的 MACE率都非常低 ? 僅證明９個月，對于接受 PCI治療的患者 Xience V/Promus支架療效和安全性接近 Cypher selcet + 支架 15 EXCELLENT trial Efficacy of Xience174。/Promus? Versus CYPHER174。 to rEduce Late Loss in stENT HyoSoo Kim et al. Seoul National University Hospital,Seoul,Korea 16 研究目的和試驗終點 ?研究目的 – 證明９個月時晚期管腔丟失 Xience174。/Promus? Stent (n=935) 不劣于 CYPHER174。 Stent (n=266) ?試驗終點 – 主要終點 ? ９個月時的節(jié)段內(nèi)晚期管腔丟失 – 次要終點 ? ９個月時支架內(nèi)晚期管腔丟失 ? 12個月時 TLR ? 12個月時 TLF（ posite of death, MI, or ischemiadriven TLR) 17 主要終點 ９個月時的節(jié)段內(nèi)晚期管腔丟失 Kim et al. Presented at TCT 2020 in Washington, DC. InSegment Late Loss (mm) Noninferiority p= Superiority p= 177。 mm 177。 mm Xience174。/Promus? Stent (n=935) CYPHER174。 Stent (n=266) 18 次要終點 ９個月時支架內(nèi)晚期管腔丟失 Kim et al. Presented at TCT 20
教學課件相關(guān)推薦
鄂ICP備17016276號-1